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CHAPTER 1: INTRODUCTION

Characterized by a high-energy manic phase and a low-energy depressive phase, bipolar
disorder affects more than 45 million people globally. Bipolar is a complex multigenic disorder
with an etiology that is still being defined (Ghadiri et al., 2016). For example, pharmaceutical
therapies primarily used to treat bipolar are still being elucidated (Coyle and Duman, 2003). In
theory, according to the myo-inositol depletion hypothesis, these drugs appear to work in part by
decreasing the myo-inositol levels of the phosphatidyl-inositol (PI) signaling pathway (Harwood,
2004). This suggests individuals with bipolar may have higher concentrations of myo-inositol
compared to a healthy neurotypical (or non-bipolar disorder). One possible reason for the increase
in available myo-inositol could be the expression of mRNA for enzymes responsible for myoinositol synthesis are upregulated in individuals with bipolar.

Shedding additional light on underlying genetic factors predisposing people to develop
bipolar disorder may provide novel therapeutic targets. Current therapies have a range of efficacy,
each laden with a variety of negative side effects such as nausea, diarrhea, excessive urination,
cognitive impairment, and tremors (Stoll et al., 1999, Coyle and Duman, 2003). These may include
Lithium, Valproate, and/or Carbamazepine, which are consistently used in the clinical setting,
although their modes of action remain unclear. For that matter, details of bipolar pathophysiology
itself are uncertain. Further study on bipolar-associated genes may provide a deeper understanding
of bipolar pathophysiology and perhaps lead to the development of novel therapies with fewer
negative side effects.

Bipolar is “a ‘cyclic’ or ‘periodic’ illness, with patients cycling ‘up’ into a manic or mixedmanic episode, then returning to normal, and cycling ‘down’ into a depressive episode from which
1

they likewise eventually more or less recover” (Association, 2000). Bipolar is characterized by
extremes. For example, in her book “An Unquiet Mind: A Memoir of Moods & Madness,” Kay
Redfield Jamison, Professor of Psychiatry at Johns Hopkins University School of Medicine,
described her experience with bipolar:
“When you’re high it’s tremendous. The ideas and feelings are fast and
frequent like shooting stars, and you follow them until you find better and
brighter ones. Shyness goes, the right words and gestures are suddenly there,
the power to captivate others a felt certainty…Feelings of ease, intensity,
power, well-being, financial omnipotence, and euphoria pervade one’s
marrow. But, somewhere, this changes. The fast ideas are far too fast, and
there are far too many; overwhelming confusion replaces clarity. Memory
goes. Humor and absorption on friends’ faces are replaced by fear and
concern. Everything previously moving with the grain is now against – you
are irritable, angry, frightened, uncontrollable, and enmeshed totally in the
blackest caves of the mind” – pg. 67 (Jamison 1995).

While the manic phase may last several days or a couple of weeks, the depressive phase
may last a few weeks or several months. A person may also experience going through rapid cycles
of mania and depression. There are primarily three types of bipolar disorder: type 1, type 2, and
cyclothymia (or cyclothymic disorder). Type 1 is characterized by a manic phase lasting for at
least seven days (or severe enough to warrant a hospital admittance) along with a depressive
episode lasting at least two weeks. Individuals with type 2 experience fewer extreme symptoms of
mania (hypomania) and longer depressive episodes. Individuals with cyclothymia cycle through
phases of hypomania and depression that are not as severe as type 1 and 2 (Goodwin and Jamison,
2007).
The symptoms associated with the highs (mania or hypomania) and lows (depression) of
bipolar are evidence of changes in emotion regulation. These include learning, memory, cognitive
control processes, executive function, and behavior. Previous studies have observed various
abnormalities in volume, metabolism, and number of oligodendrocytes in between the prefrontal
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cortex and limbic system of individuals with bipolar disorder (Mahon et al., 2010). Such differences
have been observed specifically in the orbitofrontal cortex, dorsomedial prefrontal cortex, anterior
cingulate cortex, and ventrolateral prefrontal cortex (Phillips et al., 2008). Similar differences have
been found in regions within the limbic system including the limbic cortex, cingulate gyrus,
striatum, parahippocampal gyrus, dentate gyrus, hippocampus, subicular complex, amygdala and
hypothalamus ((Phillips et al., 2008, Mahon et al., 2010). These areas of the prefrontal cortex and
limbic system work together in regulating emotions, making decisions, and cognitive processes
through tracts of white matter connecting them.

A. Bipolar Disorder Pathophysiology

Previous studies have found damaged superficial white matter tracts connecting various
parts of the prefrontal cortex with centers of the limbic system processing emotion in patients with
bipolar disorder (Versace et al., 2008, Zhang et al., 2018) (Rajmohan and Mohandas, 2007). Such
damage can be caused by modulations to intracellular communications in oligodendrocytes and/or
neurons that make up these superficial white matter tracts. For example, the higher myo-inositol
concentration the myo-inositol depletion hypothesis suggests changes in the phosphatidylinositol
biphosphate signaling pathway (PIP2) pathway may damage these superficial white matter tracks.
The affected communication between these specific parts of the brain leads to disruptions in
emotional regulation, executive functions, self-control, memory formation, etc. (Cendra et al.,
2013).
Substantial evidence of structural differences including atrophy within the frontal lobe and
increased incidence of signal hyperintensities on diffusion-weighted magnetic resonance imaging
(MRI) in white matter tracks connecting the frontal lobe with the limbic system were found to be
3

more common in the brain of unipolar and bipolar depressed patients (Videbech, 1997). White
matter lesions or damaged white matter appear as signal hyperintensities on MRI images. Damaged
white matter can be detected using diffusion-weighted MRI, which uses fractional anisotropy to
measure the restriction of diffusion of water molecules (Zhang et al., 2018). A fractional anisotropy
value of 0 indicates unrestricted diffusion of water molecules in all directions and a value of 1
signals diffusion occurs along one axis and is fully restricted along other directions. This allows
scientists to distinguish axons from surrounding tissue. Water molecules with fractional anisotropy
values closer to 1 indicate regions where water is confined within cell membranes and can only
diffuse along one axis. Within the brain, this occurs in axons. Whereas an area of water molecules
with a fractional anisotropy value closer to 0 is not restricted by cell membranes. These reduced
fractional anisotropy values have been associated with cerebrospinal fluid, local edema, changes in
axonal morphologic structure and compromised myelin structure (Versace et al., 2008). One bipolar
disorder study comparing the fractional anisotropy of white matter tracks connecting the prefrontal
cortex and limbic system, found subjects with bipolar had aberrant fractional anisotropy, a
significant negative correlation between age and fractional anisotropy, along with a significant
negative correlation between medication load and fractional anisotropy (Versace et al., 2008).
Another study found reduced fractional anisotropy in the superficial white matter in the bipolar
patients compared to the healthy controls in various areas of the prefrontal cortex (Zhang et al.,
2018).
One of the causes of reduced fractional anisotropy is aberrant myelin sheaths – a type of
white matter damage (Phillips et al., 2008). The myelin sheaths of oligodendrocytes are the defining
feature of white matter. By wrapping axons that connect neurons between regions of the prefrontal
cortex and limbic system, oligodendrocytes provide protection from the surrounding extracellular
environment. They also increase the speed of action potentials traveling down the axon by forcing
the signal to “jump” between each myelin sheath. Damage to myelin sheaths of oligodendrocytes
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can expose the axon, cause localized inflammation, and interfere with signal transduction down the
axon. The evidence presented by the fractional anisotropy studies points to abnormal myelin
sheaths (Phillips et al., 2008). Damaged myelin sheaths are the hallmark of multiple sclerosis, but
are associated with brain cancers, spinal injury, major depressive disorder, and bipolar disorder
(Mahon et al., 2010).
Glial reduction, signs of apoptosis, increased inflammation, decreased numerical density
of grey matter, oligodendrocyte abnormalities, myelin pallor in the prefrontal cortex, anterior
cingulate cortex and deep white matter have been associated with bipolar disorder (Mahon et al.,
2010). One study found statistically significant lower myelin staining in major depressive disorder
and bipolar depression compared to healthy control (Regenold et al., 2007). Disruptions to the
cytoarchitecture of oligodendrocytes and neurons cause a fundamental alteration in cell resiliency
and plasticity in these regions involved in emotion generation and regulation.
These previous studies support a hypothesis that oligodendrocyte myelin and neural axon
cell damage localized to white matter connections between cognitive and emotional areas of the
brain may be correlated with bipolar disorder (Mahon et al., 2010). The myo-inositol depletion
hypothesis connects observations made on the modes of action of various bipolar therapies with
observed anatomical differences in bipolar patients. Previous studies also reported observable
differences in myo-inositol concentrations in the frontal lobes of people with bipolar, suicide
victims and Major Depressive Disorder (Shimon et al., 1997). As myo-inositol is a precursor for
the PIP2 pathway, it provides a possible explanation (or at least a contributing factor) to the
observed white matter lesions within the brain of individuals with bipolar.

i.

Cellular-neurology pathophysiology

5

The PIP2 cascade, in concert with other protein pathways, regulates cytoskeletal
construction, Ca2+cytosol levels, cell membrane integrity, apoptosis, ATP production, etc.
Alterations of the PIP2 cascade likely contribute to drastic changes in cell growth, morphology,
function, and survival, as the cascade is integral to so many vital cell functions. If this occurs in
developing neurons, it can stunt the progress of axon growth cones as neurons search for new
synaptic connections. To that end, one study found lithium, VPA and carbamazepine blocked the
collapse of sensory neuron growth cones and expanded the growth cone area. These effects were
reversed when myo-inositol was added to the medium (Ohnishi et al., 2007a).
While alterations to the PIP2 pathway are more likely to affect a neuron while it is growing
than a mature neuron, the story is different for oligodendrocytes. A PIP2 cascade glitch could cause
any number of problems during the lifecycle of the oligodendrocyte, because of its involvement in
cytoskeletal construction and influence on mitochondria (Streck et al., 2014). The function of
oligodendrocytes is wrapped up in their ability to maintain healthy myelin sheaths (Regenold et al.,
2007). If the myelin sheath degrades, signal propagation down the axon is directly affected (Mahon
et al., 2010). The signal may take longer, get disconnected by the immune system's inflammatory
response to myelin degradation, or be confused because areas along the axon are exposed to
neurotransmitters in the surrounding extracellular matrix due to myelin degradation. By a wide
range of means, the signal is affected (Zhang et al., 2018).

ii.

PIP2 pathway

Malfunctions of the PIP2 pathway, vital to maintaining a healthy cell, can contribute to the
development of white matter tract lesions between the cognitive and emotional centers of the brain.
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The PIP2 cascade is activated by G protein-coupled receptor (GPCR) that need to translate an
extracellular signal to an intracellular signal.

Figure 1. The PIP2 Cascade: Activated by certain GPCR receptors, the PIP2 Cascade begins when PLC cleaves PIP2
producing IP3 and DAG. IP3 signals the release of Calcium ions from the ER. DAG activates PKC. These second
messengers regulate cytoskeletal construction, cytosol levels of Ca2+, cell membrane integrity, apoptosis, etc.(the myoinositol synthetic pathway is pictured on the left) (made with biorender.com)

When a GPCR linked to the phosphatidylinositol (PIP2) system is activated by the
appropriate ligand the alpha subunit (alpha q) dissociates from the GPCR complex and activates
phospholipase C (PLC) which in turn hydrolyses phosphatidylinositol into inositol-1,4,5trisphosphate (IP3) and diacylglycerol (DAG). IP3 activates IP3 receptors in the endoplasmic
reticulum membrane releasing Ca2+ into the cytosol from the endoplasmic reticulum.
Released Ca2+from the endoplasmic reticulum is a 2nd messenger participating in several
pathways as well. Ca2+ ions can activate caspase-mediated apoptosis, activate Ca2+ dependent
proteins, and increase mitochondria membrane permeability. Consequently, releasing reactive
oxygen species, reducing mitochondrial ATP synthesis, modulating cytoskeletal construction
and/or cell membrane integrity. Increased intracellular Ca2+ has been described in bipolar disorder
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(Machado-Vieira et al., 2009). Treatment with Li+ increases Bcl-2, a neuroprotective protein that
downregulates endoplasmic reticulum calcium release (Machado-Vieira et al., 2009).
DAG activates protein kinase C (PKC) enzymes (Bronson and Konradi, 2010). PKC enzymes
are kinases which phosphorylate other proteins, and therefore are integral to several intracellular
pathways. PKC family enzymes modulate neuronal development, excitability, death, and
consequently learning and memory. This is because PKC enzymes are involved in most neuronal
processes such as neurotransmitter release and uptake, cytoskeletal construction, cell membrane
integrity, regulating gene expression, and receptor and ion channel function (Bronson and Konradi,
2010).

B. Myo-inositol Depletion Hypothesis

The availability of the PIP2 precursor, myo-inositol, influences how active the PIP2 pathway
can be. Several studies have begun to create a picture of the PIP2 pathway’s role in maintaining cell
homeostasis . Previous studies have provided evidence to support that Lithium and VPA can affect
how much myo-inositol is available to the cell (Ohnishi et al., 2007a, Dixon and Hokin, 1997, Coyle
and Duman, 2003). According to the myo-inositol depletion hypothesis, Lithium and VPA
depletion of intracellular myo-inositol reduces symptoms of mania (Harwood, 2004).
Previous studies have supported the myo-inositol depletion hypothesis in that the amount
of available myo-inositol may be correlated with symptoms and treatment of bipolar disorder
(Chengappa et al., 2000). In an animal model study, treatment with Lithium lowered intracellular
myo-inositol concentration by 30% in rat cerebral cortex (Harwood, 2004). The preferred therapies,
Lithium and VPA reduce symptoms of the manic phase, and lower intracellular myo-inositol levels.
(Machado-Vieira et al., 2009); (Coyle and Duman, 2003).
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i.

Myo-inositol Biosynthesis
Myo-inositol is a precursor of the membrane phospholipid, phosphatidylinositol (PI), and

its phosphorylated derivatives phosphatidylinositol phosphates (PIP) (Ohnishi et al., 2007a). The
cell has 3 sources of myo-inositol: it can snag some floating by in the extracellular space, it can
synthesize some de novo from glucose-6-phosphate, or it can recycle the 2nd messenger IP3 back
into myo-inositol (Figure 2).

Figure 2: Sources of Myo-inositol: The cell has three sources of myo-inositol: De novo synthesis, recycling from IP3,
and extracellular capture. The Enzyme MIPs (ISYNA1) converts Glucose-6-phosphate to InsP1, beginning de novo
synthesis. The Enzyme IMPase2 (IMPA2) begins the conversion of new and recycled InsP1 to myo-inositol. (made with
biorender.com)

The de novo synthesis of myo-inositol begins as the enzyme myo-inositol 1-Phosphate
Synthase (MIPS) converts glucose-6-phosphate to myo-inositol 1 phosphate (InsP1) (Stoll et al.,
1999). The cell can also recycle the 2nd messenger inositol (1,4,5) triphosphate (IP3) back into
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InsP1. The enzymes myo-inositol monophosphatase 1 & 2 (IMPase1 & IMPase2) then catalyze
the dephosphorylation of InsP1 to myo-inositol (Coyle and Duman, 2003) (Figure 2).
Out of the genes involved in the synthesis of myo-inositol, the genes coding for MIPs
(ISYNA1) and IMPase2 (IMPA2) were selected for this study (Coyle and Duman, 2003, Stoll et al.,
1999). Previous studies provide evidence Lithium and VPA interact with these proteins. The
resulting changing concentrations of myo-inositol may correlate with observed differences: include
single nucleotide polymorphisms, location within a bipolar susceptibility locus on chromosome 18,
in each gene (Dimitrova et al., 2005); (Agam et al., 2009). There may be genetic variation in these
genes in people with bipolar disorder.
The homolog to ISYNA1 in yeast (INO1) is commonly used to study the function of
ISYNA1. The transcription of INO1 is regulated by extracellular myo-inositol levels, when levels
are high transcription of INO1 is repressed (Yu et al., 2017). In one study using yeast as a model
organism, human MIPs (isolated from post-mortem brain tissue) synthesis activity was reduced
by 35%, while intracellular myo-inositol concentration was reduced by 25% in cells grown in
therapeutically relevant concentrations of VPA (0.6mM) (Ju et al., 2004). MIPs requires a metal
ion, typically Mg2+, as a coenzyme. Lithium noncompetitively inhibits the activity of MIPS by
displacing Mg2+ (York et al., 1995).
Two single nucleotide polymorphisms (SNP) in the IMPA2 promoter sequence were found
preferentially transmitted to affected offspring (Sjøholt et al., 2000). One study correlated specific
IMPA2 SNPs unique to better Lithium treatment responders than non-responders, even though there
was not a significant difference specific to bipolar disorder(Dimitrova et al., 2005). One study
tested specific SNPs of IMPA2 in individuals with bipolar disorder and found the patients who had
the SNPs benefited more from Lithium treatment than other bipolar individuals(Sjøholt et al.,
2000). Lithium proposed mechanism of action is noncompetitive inhibition of the enzyme IMPase
which recycles myo-inositol (Coyle and Duman, 2003); (Machado-Vieira et al., 2009). Lithium
10

inhibits IMPase under therapeutic concentrations (~1 mM) (Ohnishi et al., 2007a). IMPA2 is
located within a susceptibility locus for bipolar on chromosome 18p11.2 (Dimitrova et al., 2005).
MIPs and IMPase2 are of interest because not only do they make myo-inositol, but they also interact
with Lithium and VPA. Even more interesting is how each interacts because each gene seems to
act differently with each drug. This suggests that genetic mutations in ISYNA1 & IMPA2 may be
contributing subtly to the development of bipolar and may also influence the efficacy of VPA
treatments.
The hypothesis of this study was bipolar patients express IMPA2 & ISYNA1 differently and
have different myo-inositol concentration levels as compared to neurotypical. This study did not
take into consideration possible causes for differences in gene expression and myo-inositol. The
difference between cyclothymia and the other two types of bipolar disorder is the shorter cycles
and was not evaluated in this study. This study aims to provide evidence of existing differences,
correlated with bipolar disorder types one and two, worth studying in more detail to better
understand the pathophysiology of bipolar.
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CHAPTER 2: METHODS

A. Cell Culture
This study was conducted using three immortalized lymphoblasts cell lines (LCLs)
obtained from the National Institute of General Medical Sciences (NIGMS) Human Genetic Cell
Repository at the Coriell Institute for Medical Research. These included bipolar 1 cells (GM07263),
bipolar 2 cells (GM05236, later replaced by GM04952) and cells from an individual not diagnosed
with bipolar (GM06138).
Each of the three lymphoblast cell lines were maintained according to NIGMS guidelines.
Cell lines were incubated at 37° C and 5% CO2, suspended in 10 – 20ml of growth media. The
RPMI 1640 growth media was supplemented with 1% pen-strep, 1% Glutamax, and 15% FBS.
During each passage, cell culture flasks were inspected visually for contamination and cell viability
densities were calculated via a hemocytometer. Each hemocytometer count was prepared as
follows: 10ul of cell culture was diluted with 10ul Trypan Blue.
Cell flasks were passaged every two to five days to maintain a live cell concentration
between 200,000 viable cells/ml - and 500,000 viable cells/ml. non-viable cell densities were not
considered in downstream cell density calculations. Cells were stored long-term in liquid nitrogen.
To prepare cells for storage, 5,000,000 live cells were pelleted via centrifugation at 100 xg for 10
minutes at 4-10°C, resuspended in freezing media (RPMI 1640, 30% FBS, 5% DMSO), then frozen
overnight in an isopropanol bath before being transferred to long-term storage.
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B. Myo-inositol Concentration Assay

Quantifying differences in myo-inositol concentration between the bipolar type 1, type 2,
and non-bipolar cell lines was another aim of this study. To that end, an initial attempt to measure
intracellular myo-inositol concentration was conducted using the PicoProbe fluorometric assay.
This approach was eventually replaced by the more cost-effective and efficient spectrophotometric
assay by Megazyme.

i.

Fluorometric Assay
This assay indirectly quantifies the amount of myo-inositol by measuring a fluorescent

product resulting from a two-step reaction. The myo-inositol concentration in each reaction is
then determined from a myo-inositol concentration standard curve.

The standard curve was generated using varying concentrations from 0-500pmol: 0, 100,
200, 300, 400, and 500pmol of myo-inositol. The assay was conducted in duplicates using 96 well
plates. Since the concentration of myo-inositol in each sample is determined from the myo-inositol
standard curve, before conducting sample trials, the myo-inositol standard curve first needed to be
generated. To each well was added: 50µl of a specific concentration of myo-inositol (diluted in
assay buffer), 43µl kit assay buffer, 2µl kit enzyme mix, 2µl kit developer, 3µl and PicoProbe™
(in DMSO). After a 30-minute incubation at 37°C, the plate is loaded into the spectrofluorometer
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and the fluorescence within each well of the plate was measured at Excitation = 535 nm and
Emission = 545/650 nm; with a 10nm excitation slit and 5nm emission slit; using Cary Eclipse
software and spectrofluorometer. To generate the standard curve, the 0 myo-inositol reading is
subtracted from each myo-inositol standard reading. The corrected RFU (relative fluorescence unit)
(isolated sample reading) is then applied to the myo-inositol standard curve to get nmol myo-inositol
in the well. The range of emissions was expanded to include more wavelengths of light. This was
done to document at what wavelength the fluorescent signal was strongest. Fluorescent signals
were reported at 587nm.

ii.

Spectrophotometry

The myo-inositol enzyme assay, Megazyme, was more efficient than the PicoProbe
fluorometric assay and therefore was used to generate the reported sample myo-inositol data. The
myo-inositol enzyme assay is based on two enzyme-facilitated reactions. Myo-inositol
dehydrogenase oxidizes myo-inositol using the enzyme cofactor NAD+ producing 2,4,6/3,5pentahydroxycyclohexanone, NADH , and H+. In the second reaction, catalyzed by diaphorase,
NADH reduces iodonitrotetrazolium chloride (INT) to an INT-formazan product. The amount of
INT-formazan, determined by the increase of absorbance at 492nm, is stoichiometric with the
amount of myo-inositol.
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The samples were derived from homogenized cell pellets normalized by weight. For two
of the three replicates 14ml cell culture was collected from each cell line. For one of the three
replicates, 10ml cell culture was collected from each cell line. Cells from each cell line were spun
at the highest speed in 50mL tubes for 15 minutes at ambient temperature. The supernatant was
disposed of and 5mL distilled water was added to each cell pellet. After rinsing the cells via vortex,
the cells were spun a second time at the highest speed for 15 minutes at ambient temperature.
Without disturbing the pellet, the supernatant was discarded, and each cell pellet was weighed. Cell
sample concentrations were normalized by weight. To determine the cell pellet weight, the weight
of the empty 50mL tube was subtracted from the total weight of the cell pellet in the tube. Cell
pellets were used immediately downstream or were stored at -20°C. Cell extracts were prepared by
resuspending each cell pellet with 5mL distilled water. Each resuspended pellet was mixed by
vortex. Each cell sample was then sonicated to lyse the cells. Then 1mL of the lysed homogenized
cell sample was centrifuged at 13,000g for three minutes. 100µl of the extract was used per reaction.
To prepare the time-sensitive assay, the reactants for each reaction were prepared in
disposable 1 cm light path cuvettes. Each assay had a blank cuvette prepared along with the various
sample cuvettes. Each cell line was represented by one sample reaction cuvette. Each cuvette
received 500µl distilled water, 100µl pH7.4 kit buffer, 20µl hexokinase (which removes any
glucose present), 100µl sample, and 100µl reconstituted ATP. Each cuvette was covered with
parafilm, mixed gently, and allowed to incubate at ambient temperature for 15 minutes. The blank
cuvette contained no cell extract.
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Figure 3. Spectrophotometric Assay Layout: A negative and positive control cuvette were measured alongside the
myo-inositol assay reaction cuvettes. (n=3) The formazan color shift in the reaction cuvettes before and after
absorbance readings is visible to the naked eye.

After incubating at ambient temperature for 15 minutes, each cuvette received 1ml pH 9.5
kit buffer, 20µl diaphorase suspension, and 500µl (light-sensitive) kit NAD+/INT. Each cuvette
was mixed gently, protected from light until reading, and the absorbance (A1) was recorded at 492
nm after approximately three minutes. After recording the absorbance (A1) of every cuvette, 20µl
myo-inositol dehydrogenase suspension was added to each cuvette to start the reaction. After gently
mixing each cuvette, the cuvettes were protected from light and incubated for about 15 minutes at
ambient temperature. The absorbance (A2) was recorded for each cuvette in the same order as
before. The recorded absorbance values and weight of the cell pellet for each cell line were used to
calculate the concentration of myo-inositol in each sample.
The amount of INT-formazan, determined by the increase of absorbance at 492nm, is
stoichiometric with the amount of myo-inositol. The increase in INT-formazan absorbance (ΔA)
was calculated by subtracting (A1) from (A2) for each cuvette. The ΔA of myo-inositol was found
by subtracting the blank ΔA from the sample ΔA. The ΔA of myo-inositol was then used to
calculate the concentration of myo-inositol.
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Once the concentration of myo-inositol in each sample cuvette was determined using the
equations provided by Megazyme, it was used to find the content of myo-inositol in each sample.
The concentration of myo-inositol was normalized by weight using the content of myo-inositol
formula: The content of myo-inositol (mg myo-inositiol/g total cells) was calculated by dividing
myo-inositol concentration by total cells weight, using the following formula:

17

C. Gene Expression Assay
i.

mRNA Extraction & Quantification
The RNA in each sample pellet was extracted using Bio-Rad’s Aurum Total RNA Mini

Kit. To prepare cell samples, 2 million live cells from each cell line were pelleted by centrifugation
at 12,5000g at ambient temperature for two minutes to collect cells from multiple cell culture flasks.
The cell pellet was centrifuged twice. The supernatant was discarded, and the pellet was
resuspended in 250 µl PBS and was either stored in the freezer at -20°C or used immediately for
RNA extraction. According to the Bio-Rad Total RNA min Kit Spin Protocol, each subsequent
centrifugation was done at 12,500g at ambient temperature. The sample pellets were centrifuged,
and the supernatant discarded. The cells were lysed and homogenized with 350µl lysis
(supplemented with 1% guanidine thiocyanate in β-mercaptoethanol) solution. 70% ethanol was
added to the cell lysate and the cell lysate was filtered through an RNA binding column by
centrifugation for one minute. The filtrate was discarded, and the column washed with 700µl low
stringency wash via centrifuging for one minute. To remove genomic DNA, the column was
incubated at ambient temperature with 80µl DNase (RNase free DNase reconstituted in 250 μl 10
mM Tris, pH 7.5) for 20 minutes. The column was then washed first with 700µl high stringency
(guanidinium chloride) buffer by centrifugation for one minute, then 700µl low stringency buffer
by centrifugation for one minute. This was followed by an additional centrifugation for two minutes
to remove the residual wash solution. The column was transferred to capped microcentrifuge tubes
and treated with 80µl elution solution for one minute at ambient temperature. The column was then
centrifuged for two minutes to elute the total RNA. The RNA elutes for each cell line sample were
used immediately or stored at -80°C. The mRNA concentration was determined using UV
spectroscopy. Each eluant was diluted with nuclease-free water and absorbance was measured at
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260nm. The absorbance values were multiplied by the dilution factor (3.3) and the RNA standard
of 40µg/ml to determine RNA concentrations.

ii.

cDNA Synthesis

The eluted RNA was reverse transcribed using Bio-Rad’s iScript Reverse Transcription
Supermix for RT-qPCR kit. A 96-well assay plate was prepared, on ice, for reverse transcription
as follows: a reverse transcriptase (RT) reaction and no-RT reaction for each sample elute. Each
20µl reaction received nuclease-free water, mRNA elute, and either 4µl RT supermix or no-RT
supermix. The amount of mRNA elute (and nuclease free water) in each reaction was based on
RNA concentration and qPCR template calculations. The sealed plate was placed in a Bio-Rad RT
quantitative thermocycler and cDNA was synthesized using the following protocol: priming for
five minutes at 25°C, Reverse transcription for 20-minute 46°C, RT inactivation for one minute at
95°C. After reverse transcription the cDNA was used immediately or stored at -20°C for future use.

iii.

Quantitative PCR

The relative gene expression of IMPA2 & ISYNA1 in bipolar 1 and 2 was measured using
the Bio-Rad SYBR Green PCR system: commercially available PrimePCR™ SYBR® Green
Primer assays (primers), PrimePCR™ SYBR® Green assays (commercial templates),
SsoAdvanced Universal™ Supermix, and nuclease-free water. For each qPCR assay, a 96 well
assay plate was prepared to amplify each GOI from each of the three cell lines along with the
following controls. For each SYBR Green reaction with RT sample product, a corresponding SYBR
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Green reaction with noRT sample product was included as a negative control. Each qPCR assay
included reactions with commercial templates for each primer as a positive control and reactions
without templates as a negative control. Each qPCR assay also included supermix and nucleasefree water reactions, and nuclease-free water only reactions contamination controls. Each step of
the workflow included controls for genomic DNA contamination. Each RNA elute was incubated
and rinsed with DNase before reverse transcription. To detect genomic DNA, each qPCR assay
included a Bio-Rad designed DNA contamination control assay (gDNA) primer that amplifies noncoding DNA. The gDNA assay CT values were used to compare relative levels of gDNA
contamination present in different samples to determine if the qPCR assay results may be affected.
For each SYBR Green qPCR assay, the reaction wells of the 96 well plate were prepared,
on ice, as follows: nuclease-free water (volume based on template volume), 10µl SsoAdvanced
Universal Supermix, 1µl primer, and appropriate volume of (commercial or sample) template was
added to each well. The volume of template added to each reaction was calculated from RNA
concentration and qPCR calculations. The qPCR assay was conducted using the following protocol:
after two minutes at 95°C for template denaturation, the temperature was raised from 65°C to 95°C
in 5°C increments for five seconds, and the melting points were recorded. Immediately thereafter,
40 PCR cycles were performed by repeating the following thermocycling profile: denaturation at
95°C for five seconds, then annealing and extension at 62°C for 30 seconds. At the end of the PCR
amplification, a second melt curve was obtained, the temperature was raised from 65°C to 95°C in
5°C increments for five seconds, and the melting points were recorded. After completing the PCR
amplification, the 96 well PCR plate was stored at -20°C for use in gel electrophoresis. To visualize
the qPCR assay product lengths, samples from the qPCR amplicon were run on a 5% agarose gel
containing 0.006% ethidium bromide, using Tris/Borate/EDTA (TBE) as the running buffer. The
Ultra-Low Range DNA Ladder (Invitrogen) was used to determine product length in base pairs.
The DNA was electrophoresed at 100V for 30 minutes and imaged under UV light.
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iv.

Relative Gene Expression Determination

Relative gene expression of ISYNA1 & IMPA2 was determined using the amplification
curve CT values by the ΔΔ CT calculation method. Also known as the Livak method, it is used to
determine the relative difference in the expression level of a target gene in test samples compared
to a calibrator sample. The non-bipolar samples served as the calibrator to measure relative gene
expression in bipolar 1 and 2 samples. The ΔΔ CT assumes that both target and reference genes are
amplified with efficiencies near 100% and within 5% of each other. The percent efficiency of the
PrimePCR SYBR Green assay primers are as follows: ISYNA1 = 99%, IMPA2 = 96%, and ACTG1
= 99% (Bio-Rad). Using the ΔΔ CT method, first, the relative difference in CT was calculated
between each GOI - ISYNA1 & IMPA2 - and the average expression of the reference gene - ACTG1.
This Δ CT for each gene was then used to calculate ΔΔ CT (for bipolar 1 and 2) using the non-bipolar
samples as the calibrator.
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CHAPTER 3: RESULTS

For this study, a myo-inositol concentration assay was used to measure intracellular myoinositol. In addition, Real-Time quantitative PCR (RT-qPCR) was done to measure relative IMPA2
& ISYNA1 gene expression. Both assays were done using immortalized lymphoblast cell lines
initially derived from three different individuals: an individual with bipolar type 1, one with type
2, and a non-bipolar (healthy control). Lymphoblasts were chosen as the model since several
previous studies have already used them and the cell lines tend to be more robust in cell culture
(Milanesi et al., 2017); (Walss-Bass and Fries, 2018); (Fries et al., 2017).

Myo-inositol

concentrations within the same three cell lines were measured using a myo-inositol assay kit. For
each experiment, the mean from multiple assay replicates was used to represent the results for
relative gene expression and myo-inositol concentration respectively.

A. Myo-inositol Concentration
i.

Fluorometric Assay

For the fluorometric assay, the myo-inositol concentration in each reaction is determined
from a myo-inositol concentration standard curve. Initial standard curve generation trials produced
inconsistent data. The assay methodology finally produced a standard curve (in triplicate) after a
few optimization (5) trials. Due to the extensive optimization involved in the fluorometric assay,
the spectrophotometric assay was used instead.
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Figure 4: Myo-inositol Standard Curve Initial Trial: Standard Curve of myo-inositol (n=3).

Figure 5: Myo-inositol Standard Curve Fifth Trial: Standard Curve (n=3)

ii.

Spectrophotometric Assay

The average myo-inositol concentration from bipolar type 1, type 2, and non-bipolar did
show a statistically significant difference. While myo-inositol concentrations were similar
between bipolar 2 and non-bipolar samples (1.8 and 1.7 myo-inositol g/l / sample g/l
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respectively); the concentration of myo-inositol in the bipolar 1 sample (4.7 myo-inositol g/l /
sample g/l) was almost three times as high (F = 12.5, p < 0.05). On average, the bipolar 1 sample
had a higher concentration of myo-inositol than bipolar 2 or non-bipolar samples.

Figure 6: Mean myo-inositol concentration: in bipolar type 1, type 2, and non-bipolar cell extracts, n= 3 (F = 12.5, p
< 0.05 by ANOVA).

B. Relative Gene Expression

Measuring the relative gene expression differences of IMPA2 & ISYNA1, between the
bipolar type 1, type 2, and non-bipolar cell lines was another aim of this study. The two genes of
interest (GOI), IMPA2 & ISYNA1, code for enzymes that are responsible for catalyzing specific
steps within the myo-inositol biosynthesis pathway. They interact with Lithium and VPA in unique
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ways. Previous studies have documented differences in each correlated with bipolar. Detecting
whether either is expressed differently in bipolar provides further information on the
pathophysiology of bipolar disorder. Relative IMPA2 & ISYNA1 gene expression was determined
by quantitative PCR using RNA extracted from the three cell lines.
Figure 7 shows the relative gene expression of ISYNA1 mRNA by RT-qPCR. Relative
ISYNA1 expression in the bipolar 2 cells was 0.47-fold higher than the non-bipolar control. Relative
ISYNA1 expression in the bipolar 1 cells was 0.76-fold higher than the non-bipolar control.

Figure 7:ISYNA1 gene expression in bipolar type 1 and type 2 relative to non-bipolar, n=3.

.

Figure 8 shows the amplification curves of ACTG1 RT, ISYNA1 RT, and gDNA RT RTqPCR reactions in triplicate. ISYNA1 cDNA had CT values ranging between 20 and 22 across
bipolar type 1, type 2, and non-bipolar cell lines as expected. The reference gene ACTG1 had CT
values between 13 and 15 across type 1 and 2, and non-bipolar cell lines as expected. The CT values
for the gDNA contamination assay were > 31 and therefore considered negligible.
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Figure 8: Amplification Curves: ACTG1, ISYNA1 and gDNA RT-qPCR reaction wells show the thresh hold cycle (Ct)
for each primer assay

Figure 9 shows the relative gene expression of IMPA2 mRNA by RT-qPCR. Relative
IMPA2 expression in the bipolar type 2 cells was 2-fold higher than non-bipolar IMPA2
expression, and bipolar type 1 lymphoblasts had 2.1-fold higher IMPA2 expression compared to
the non-bipolar control.

Figure 9: IMPA2 gene expression in bipolar 1 and bipolar 2 disorder relative to non-bipolar disorder, n=3.
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Figure 10 shows the amplification curves of ACTG1 RT, IMPA2 RT, and gDNA RT RTqPCR reactions in triplicate. IMPA2 cDNA had CT values ranging between 21 and 28 across bipolar
type 1, type 2 and non-bipolar cell lines. The reference gene ACTG1 had CT values between 13 and
15 across bipolar type 1, type 2, and non-bipolar cell lines. The CT values for the gDNA
contamination assay were > 31 and therefore considered negligible.

Figure 10: Amplification curves: The amplification curves of ACTG1, IMPA2 and gDNA RT-qPCR reaction wells
show the thresh hold cycle (Ct) for each primer assay.

i.

Genomic DNA Contamination Quantification

Genomic DNA present, and potentially amplified, during qPCR may contribute to SYBR
Green reaction signals. This begs the question of how much of the total reaction signal reflects the
target sequence. Relative genomic contamination was determined to be negligible using the gDNA
Contamination Control Assay provided by Bio-Rad. A gDNA CT values > 35 indicates below single
copy detection (no gDNA present). For gDNA CT values < 35, the following formula, | (GOI CT)
– (gDNA CT) | = Δ Cq, determines the relative contribution of gDNA to the sample signal. Each Δ
CT value corresponds with a percent genomic contribution to the sample signal. For this study, any
genomic contamination < 12.5% genomic contribution was considered negligible.
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ii.

Melt Curve Analysis Results

According to the melt curve analysis (figure 11) performed at the end of the qPCR, the
melt peaks were approximately: ISYNA1 - 88 Tm C°, IMPA2 - 84.5 Tm C°, and ACTG1 - 85
Tm C° According to primer assay validation reports, each amplicon Tm C° was: ISYNA1 = 88,
IMPA2 = 84.5, ACTG1 = 85.5. Because the melt curve analysis closely matched the expected
Tm, it is likely that each primer assay amplicon was the expected length. The lack of melt peaks
below 80 Tm C° in the melt curve analysis showed no primer dimers contributed to qPCR
signals.

Figure 11: Melt Curve Analysis: melt peaks for each primer assay were (A) IMPA2 = 84.5 Tm C° , (B) ISYNA1 = 88
Tm C°, (C) ACTG1= 85 Tm C° and (D) gDNA = 81 Tm C°.
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iii.

Gel Electrophoresis Results
The results of running representative samples of each primer assay on a 5% agarose gel

stained with EtBr also supported the expected product was obtained. Figure 12 shows, from left to
right, the two control templates (CT); gDNA from a no RT well & RT well; and a sample from
ACTG1, IMPA2, and ISYNA1 RT wells. The two CT and the IMPA2 amplicons are between 50
and 75 base pairs; the gDNA amplicons and the ISYNA1 amplicons are close to 150 base pairs; and
the ACTG1 amplicon is close to 200 base pairs. As evident by the location of the bands in the gel
in figure 13, the cDNA samples and commercial templates amplified were the expected amplicon
lengths.

Figure 12: 5% agarose gel dyed with EtBr. From left, well 1: Ladder 300-10 bp; well 2: ISYNA1 CT; well 3: IMPA2
CT; well 4: gDNA from bipolar 2 no RT; well 5: gDNA from bipolar 2 RT; well 6: ACTG1 of bipolar 1 RT; well 7:
IMPA2 of BD2 RT well 8: ISYNA1 of BD2 RT.

The results of the genomic contamination control assay (gDNA), melt curve analysis, and
5% agarose gel validate that the sample signal CT values represent the target amplicons. The
genomic contamination control assay did detect some genomic contamination contributing to
sample signals, which was considered negligible. The melt curve analysis showed no evidence of
primer dimers and confirmed the amplicons for each primer assay were the expected length. The
clear banding pattern in the 5% agarose gel shows each amplicon at its expected length. The results
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of the genomic contamination control assay, melt curve analysis, and 5% agarose gel, validate the
sample signals CT values.
The major objective of this study was to measure possible differences in myo-inositol
concentration and ISYNA1 and IMPA2 gene expression between each type of bipolar compared to
healthy control. The relative gene expression of ISYNA1 was found to be 0.47-fold (bipolar 2)
and 0.76-fold (bipolar 1) higher compared to non-bipolar control. The relative gene expression of
IMPA2 was 2-fold (bipolar 2) and 2.1-fold higher compared to non-bipolar control. The
concentration of myo-inositol was 13.5 g/100g in non-bipolar, 14.5 g/100g in bipolar 2, and 48.2
g/100g.
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CHAPTER 4: DISCUSSION
Measuring possible differences in myo-inositol concentration and ISYNA1 and IMPA2 gene
expression between each type of bipolar disorder compared to neurotypical were the major
objectives of this study. The results of this study show both ISYNA1 and IMPA2 are expressed
relatively higher in bipolar disorder, further their expression is even higher in bipolar type 1
compared to type 2. Simultaneously, the myo-inositol concentration is significantly higher in type
1 compared to type 2 and non-bipolar disorder. This is one of the first studies to measure relative
differences in myo-inositol concentration and gene expression between the different types of
bipolar. This and previous studies from a broader body of literature demonstrate differences
associated with bipolar at the genetic, molecular, cellular, and neural circuitry levels. A population
study comparing the expression of these genes between different types of bipolar could shed light
on how the expression of these genes contribute to the severity of bipolar symptoms.
The focus of this study was to see if bipolar disorder patients express IMPA2 & ISYNA1
differently and have different myo-inositol concentration levels. This study found both ISYNA1 and
IMPA2 expressed relatively higher in bipolar compared to non-bipolar; and bipolar type 1 had
significantly higher concentrations of myo-inositol compared to type 2 and non-bipolar disorder.
Not only were both genes expressed higher in bipolar compared to non-bipolar, but each gene was
also expressed slightly higher in bipolar type 1 and 2. Interestingly, the results showed the
expression of IMPA2 was more than twice as high as ISYNA1 in both types of bipolar compared to
non-bipolar. The concentration of myo-inositol in bipolar1 was significantly higher than either type
2 or non-bipolar disorder.
These results support the hypothesis that increased available myo-inositol maybe directly
contributing to bipolar symptoms. The relatively higher expression of IMPA2 and ISYNA1 in both
types of bipolar compared to non-bipolar supports this hypothesis because more Impase2 and MIPs
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could be making more myo-inositol available to the cell to use in the PIP2 network. Similarly, a
postmortem study found frontal brain region IMPA1 expression levels were not different, but
IMPA2 transcription was significantly upregulated in bipolar compared to non-bipolar (Ohnishi et
al., 2007b). However, a different study measuring relative gene expression in lymphoblasts
exhibiting high calcium ion levels in bipolar compared to healthy control found lower IMPA2
expression in the type 1 cells (Yoon et al., 2001). Another study also found IMPase (not specifically
IMPA1 or IMPA2) mRNA was downregulated in bipolar lymphoblasts and Lithium responders
had even lower expression (Agam et al., 2009). Expression of IMPA2 in bipolar requires more
attention considering the conflicting results of this and previous studies. Additional studies
comparing the expression of IMPA1 to IMPA2 specifically will provide a clearer understanding of
each gene’s involvement. Relative gene expression of IMPA2 studies, using large population sizes,
could provide clarifying results.
It would be interesting to compare how the cells regulate the expression of either ISYNA1
and/or IMPA2 in response to Lithium and/or VPA treatment in a larger population study. Previous
studies have demonstrated Lithium and VPA interactions with MIP1 (ISYNA1) and IMPA1, and
their fungal counterparts (Murray and Greenberg, 2000); (Dimitrova et al., 2005). This study did
not consider what phase the lymphoblast donors were in nor what treatments they were on at the
time of donation. Measuring differences in myo-inositol concentration and ISYNA1 & IMPA2 gene
expression between the manic and depressive phases will help us fine tune treatment methods for
each phase of the disorder.
The observed statistically significant difference in myo-inositol concentration in bipolar
type 1 compared to type 2 and non-bipolar may also correlate with the more extreme symptoms of
the in type 1 bipolar disorder. The results of this and previous studies suggest that the availability
of myo-inositol may contribute to the severity of the symptoms of bipolar (Vaden et al., 2001).
Additionally, studies have found reduced inositol levels in the brain of suicide victims and bipolar
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patients (Shimon et al., 1997). During clinical trials, bipolar patients who were treated with inositol
saw improvements in depressive symptoms (Chengappa et al., 2000). After all, the longer and more
intense phases of bipolar type 1 is what differentiates type 1 from type 2 bipolar disorder
(Association, 2000).
A future comparison study of individuals during the different phases of bipolar disorder
could provide a clearer picture. It would be interesting to find out if cells change the expression of
either ISYNA1 or IMPA2 in response to changes in myo-inositol concentration. The results of these
studies may provide insight into biochemical differences between the two phases of bipolar. This
may provide a basis for personalized treatment specific to the manic phase or the depressive phase.
The existing evidence points to several intracellular factors all of which affect the white
matter connecting the prefrontal cortex and limbic system (Phillips et al., 2008). As stated
previously, bipolar is a multi-genic disorder with several genes contributing in subtle yet critical
ways to the pathophysiology of the disorder. IMPase and MIPs are not the only enzymes involved
in myo-inositol synthesis (Harwood, 2004). Conducting future studies on each enzyme (and
respective gene) related to myo-inositol metabolism is crucial to creating a more comprehensive
picture of the PIP2 intracellular pathway and its relationship with bipolar disorder.
Furthermore, evidence indicates genes related to oligodendrocytes and myelin appear to be
abnormally expressed in schizophrenia and bipolar (Mahon et al., 2010). One study found the
expression of 26 genes involved in apoptosis signaling pathways were modulated by Lithium
therapy (Fries et al., 2017). Several studies have observed a variety of genetic differences between
Lithium responders and non-responders (Walss-Bass and Fries, 2018). Due to myo-inositol’s
integral role in maintaining cell integrity of white matter tracts connecting the frontal lobe and
limbic system, abnormalities in genes responsible for making myo-inositol may be contributing to
bipolar.
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Shedding light on myo-inositol’s integral role in maintaining cell integrity of white matter
tracts connecting the frontal lobe and limbic system, and possible abnormalities in genes
responsible for making myo-inositol can provide novel therapeutic targets for bipolar disorder.
Elucidating possible genetic differences unique to bipolar may help us better understand bipolar
pathophysiology which helps improve the treatment of bipolar disorder. It would be interesting to
further investigate the potential causes for the observed higher mRNA expression of ISYNA1 and
IMPA2 in bipolar.

34

APPENDIX

Figure 13: myo-inositol concentration graph for each of the three myo-inositol assays

A: Each of the myo-inositol concentration assay results

content of myo-inositol [g/100g]
bipolar
bipolar
nondisorder1 disorder2
bipolar
disorder
A
67.18
16.11
15.52
B
41.89
9.48
15.04
C
35.4
17.92
9.93
Mean
48.16
14.5
13.5
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Prime PCR Assay Info (from Validation Reports)
Amplicon length
(Bipolar)

assay design

cDNA Cq gDNA Cq cDNA Tm (C)

ISYNA1

131

exonic

21.17

26.37

88

IMPA2

64

exonic

21.11

25

84.5

ACTG1

191

N/A

14.02

20.54

85.5

gDNA

60

Validation Cq values based on threshold at 300 RFU
All commercial templates are synthetic DNA, length = 60 bp

Figure 14: Genomic Contamination Determination Table (provided by Bio-Rad)

(PrimePCR TM Assays, Panels, and Controls for Real-Time PCR Instruction Manual pg. 21)

36

REFERENCES
AGAM, G., BERSUDSKY, Y. & BELMAKER, R. H. 2009. Abnormalities of Inositol
Metabolism in Lymphocytes as Biomarkers for Bipolar Disorder. In: RITSNER, M. S.
(ed.) The Handbook of Neuropsychiatric Biomarkers, Endophenotypes and Genes:
Metabolic and Peripheral Biomarkers. Dordrecht: Springer Netherlands.
ASSOCIATION, A. P. 2000. Bipolar Disorder (DSM-IV-TR #296.0–296.89) Diagnostic and
statistical manual of mental disorders. 4rth Edition text revised ed. Washington, DC.
BRONSON, S. E. & KONRADI, C. 2010. Chapter 26 - Second-Messenger Cascades. In:
STEINER, H. & TSENG, K. Y. (eds.) Handbook of Behavioral Neuroscience. Elsevier.
CENDRA, A., M., B. K., XIAOQIAO, X. A., FRANCOIS, F., L., R. B. & D., M. K. 2013.
Modulation of the autonomic nervous system and behaviour by acute glial cell Gq
protein-coupled receptor activation in vivo. The Journal of Physiology, 591, 5599-5609.
CHENGAPPA, K. R., LEVINE, J., GERSHON, S., MALLINGER, A. G., HARDAN, A.,
VAGNUCCI, A., POLLOCK, B., LUTHER, J., BUTTENFIELD, J., VERFAILLE, S. &
KUPFER, D. J. 2000. Inositol as an add-on treatment for bipolar depression. Bipolar
Disorders, 2, 47-55.
COYLE, J. T. & DUMAN, R. S. 2003. Finding the Intracellular Signaling Pathways Affected by
Mood Disorder Treatment. Neuron, 38, 157-160.
DIMITROVA, A., MILANOVA, V., KRASTEV, S., NIKOLOV, I., TONCHEVA, D., OWEN,
M. J. & KIROV, G. 2005. Association study of myo-inositol monophosphatase 2
(IMPA2) polymorphisms with bipolar affective disorder and response to lithium
treatment. Pharmacogenomics Journal, 5, 35-41.
DIXON, J. F. & HOKIN, L. E. 1997. The antibipolar drug valproate mimics lithium in
stimulating glutamate release and inositol 1,4,5-trisphosphate accumulation in brain
cortex slices but not accumulation of inositol monophosphates and bisphosphates. Proc
Natl Acad Sci U S A, 94, 4757-60.
FRIES, G. R., COLPO, G. D., MONROY-JARAMILLO, N., ZHAO, J., ZHAO, Z., ARNOLD, J.
G., BOWDEN, C. L. & WALSS-BASS, C. 2017. Distinct lithium-induced gene
expression effects in lymphoblastoid cell lines from patients with bipolar disorder.
European Neuropsychopharmacology, 27, 1110-1119.
GHADIRI, M., NOURMOHAMMADI, I., FASIHI RAMANDI, M. & MOAZEN ZADEH, E.
2016. Association involving serotonin transporter gene linked polymorphic region and
bipolar disorder type 1 in Iranian population. Asia-Pacific Psychiatry, 8, 92-97.
GOODWIN, F. K. & JAMISON, K. R. 2007. Manic-Depressive Illness: Bipolar Disorders and
Recurrent Depression, New York, OXFORD University Press.
HARWOOD, A. J. 2004. Lithium and bipolar mood disorder: the inositol-depletion hypothesis
revisited. Molecular Psychiatry, 10, 117.
JU, S., SHALTIEL, G., SHAMIR, A., AGAM, G. & GREENBERG, M. L. 2004. Human 1-Dmyo-Inositol-3-phosphate Synthase Is Functional in Yeast. Journal of Biological
Chemistry, 279, 21759-21765.
MACHADO-VIEIRA, R., MANJI, H. K. & ZARATE, C. A., JR. 2009. The role of lithium in the
treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying
hypothesis. Bipolar Disord, 11 Suppl 2, 92-109.
MAHON, K., BURDICK, K. E. & SZESZKO, P. R. 2010. A role for white matter abnormalities
in the pathophysiology of bipolar disorder. Neuroscience and biobehavioral reviews, 34,
533-554.
MILANESI, E., VOINSKY, I., HADAR, A., MAJ, C., KELSOE, J. R., SHEKHTMAN, T.,
ZANDI, P., GOES, F., POTASH, J. B., GRESHOVITS, M., GILAD, S., GENNARELLI,
M., SCHULZE, T. G. & GURWITZ, D. 2017. M37 - RNA-Sequencing of Bipolar
37

Disorder Patients Lymphoblastoid Cell Lines Implicates A Novel Neurotrophic Factor In
The Efficacy of Lithium As Mood Stabilizing Drug. European
Neuropsychopharmacology, 27, S391-S392.
MURRAY, M. & GREENBERG, M. L. 2000. Expression of yeast INM1 encoding inositol
monophosphatase is regulated by inositol, carbon source and growth stage and is
decreased by lithium and valproate. Molecular Microbiology, 36, 651-661.
OHNISHI, T., OHBA, H., SEO, K. C., IM, J., SATO, Y., IWAYAMA, Y., FURUICHI, T.,
CHUNG, S. K. & YOSHIKAWA, T. 2007a. Spatial expression patterns and biochemical
properties distinguish a second myo-inositol monophosphatase IMPA2 from IMPA1. J
Biol Chem, 282, 637-46.
OHNISHI, T., YAMADA, K., OHBA, H., IWAYAMA, Y., TOYOTA, T., HATTORI, E.,
INADA, T., KUNUGI, H., TATSUMI, M., OZAKI, N., IWATA, N., SAKAMOTO, K.,
IIJIMA, Y., IWATA, Y., TSUCHIYA, K. J., SUGIHARA, G., NANKO, S., OSUMI, N.,
DETERA-WADLEIGH, S. D., KATO, T. & YOSHIKAWA, T. 2007b. A Promoter
Haplotype of the Inositol Monophosphatase 2 Gene (IMPA2) at 18p11.2 Confers a
Possible Risk for Bipolar Disorder by Enhancing Transcription.
Neuropsychopharmacology, 32, 1727-1737.
PHILLIPS, M. L., LADOUCEUR, C. D. & DREVETS, W. C. 2008. A neural model of voluntary
and automatic emotion regulation: implications for understanding the pathophysiology
and neurodevelopment of bipolar disorder. Molecular Psychiatry, 13, 833-857.
RAJMOHAN, V. & MOHANDAS, E. 2007. The limbic system. Indian Journal of Psychiatry,
49, 132-139.
REGENOLD, W. T., PHATAK, P., MARANO, C. M., GEARHART, L., VIENS, C. H. &
HISLEY, K. C. 2007. Myelin staining of deep white matter in the dorsolateral prefrontal
cortex in schizophrenia, bipolar disorder, and unipolar major depression. Psychiatry Res,
151, 179-88.
SHIMON, H., AGAM, G., BELMAKER, R. H., HYDE, T. M. & KLEINMAN, J. E. 1997.
Reduced Frontal Cortex Inositol Levels in Postmortem Brain of Suicide Victims and
Patietns With Bipolar Disorder. American Journal of Psychiatry, 154, 1148 -1150.
SJØHOLT, G., GULBRANDSEN, A. K., LØVLIE, R., BERLE, J. Ø., MOLVEN, A. & STEEN,
V. M. 2000. A human myo-inositol monophosphatase gene (IMPA2) localized in a
putative susceptibility region for bipolar disorder on chromosome 18p11.2: genomic
structure and polymorphism screening in manic-depressive patients. Molecular
Psychiatry, 5, 172.
STOLL, A. L., LOCKE, C. A., MARANGELL, L. B. & SEVERUS, W. E. 1999. Omega-3 fatty
acids and bipolar disorder: a review. Prostaglandins, Leukotrienes and Essential Fatty
Acids, 329-337.
STRECK, E. L., GONÇALVES, C. L., FURLANETTO, C. B., SCAINI, G., DAL-PIZZOL, F. &
QUEVEDO, J. 2014. Mitochondria and the central nervous system: searching for a
pathophysiological basis of psychiatric disorders. Braz J Psychiatry, 36, 156-67.
VADEN, D. L., DING, D., PETERSON, B. & L., G. M. 2001. Lithium and Valproate Decrease
Inositol Mass and Increase Expression of the Yeast INO1 and INO2Genes for Inositol
Biosynthesis. Journal of Biological Chemistry, 276, 15466–15471.
VERSACE, A., ALMEIDA, J. R., HASSEL, S., WALSH, N. D., NOVELLI, M., KLEIN, C. R.,
KUPFER, D. J. & PHILLIPS, M. L. 2008. Elevated left and reduced right orbitomedial
prefrontal fractional anisotropy in adults with bipolar disorder revealed by tract-based
spatial statistics. Arch Gen Psychiatry, 65, 1041-52.
VIDEBECH, P. 1997. MRI findings in patients with affective disorder: a meta-analysis. Acta
Psychiatrica Scandinavica, 96, 157-168.
WALSS-BASS, C. & FRIES, G. R. 2018. Are lithium effects dependent on genetic/epigenetic
architecture?
38

YOON, I. S., LI, P. P., SIU, K. P., KENNEDY, J. L., COOKE, R. G., PARIKH, S. V. &
WARSH, J. J. 2001. Altered IMPA2 gene expression and calcium homeostasis in bipolar
disorder. Molecular Psychiatry, 6, 678.
YORK, J. D., PONDER, J. W. & MAJERUS, P. W. 1995. Definition of a metal-dependent/Li(+)inhibited phosphomonoesterase protein family based upon a conserved three-dimensional
core structure. Proc Natl Acad Sci U S A, 92, 5149-53.
YU, W., DANIEL, J., MEHTA, D., MADDIPATI, K. R. & GREENBERG, M. L. 2017. MCK1 is
a novel regulator of myo-inositol phosphate synthase (MIPS) that is required for
inhibition of inositol synthesis by the mood stabilizer valproate. PLoS ONE, 12, 1-12.
ZHANG, S., WANG, Y., DENG, F., ZHONG, S., CHEN, L., LUO, X., QIU, S., CHEN, P.,
CHEN, G., HU, H., LAI, S., HUANG, H., JIA, Y., HUANG, L. & HUANG, R. 2018.
Disruption of superficial white matter in the emotion regulation network in bipolar
disorder. Neuroimage Clin, 20, 875-882.

39

